Generation of 3D skin equivalents fully reconstituted from human induced pluripotent stem cells (iPSCs).

Recent generation of patient-specific induced pluripotent stem cells (PS-iPSCs) provides significant advantages for cell- and gene-based therapy. Establishment of iPSC-based therapy for skin diseases requires efficient methodology for differentiating iPSCs into both keratinocytes and fibroblasts, th...

Full description

Bibliographic Details
Main Authors: Munenari Itoh, Noriko Umegaki-Arao, Zongyou Guo, Liang Liu, Claire A Higgins, Angela M Christiano
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3795682?pdf=render
id doaj-b658b103254a4087ace20e188c768ae4
record_format Article
spelling doaj-b658b103254a4087ace20e188c768ae42020-11-25T01:19:26ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-01810e7767310.1371/journal.pone.0077673Generation of 3D skin equivalents fully reconstituted from human induced pluripotent stem cells (iPSCs).Munenari ItohNoriko Umegaki-AraoZongyou GuoLiang LiuClaire A HigginsAngela M ChristianoRecent generation of patient-specific induced pluripotent stem cells (PS-iPSCs) provides significant advantages for cell- and gene-based therapy. Establishment of iPSC-based therapy for skin diseases requires efficient methodology for differentiating iPSCs into both keratinocytes and fibroblasts, the major cellular components of the skin, as well as the reconstruction of skin structures using these iPSC-derived skin components. We previously reported generation of keratinocytes from human iPSCs for use in the treatment of recessive dystrophic epidermolysis bullosa (RDEB) caused by mutations in the COL7A1 gene. Here, we developed a protocol for differentiating iPSCs into dermal fibroblasts, which also produce type VII collagen and therefore also have the potential to treat RDEB. Moreover, we generated in vitro 3D skin equivalents composed exclusively human iPSC-derived keratinocytes and fibroblasts for disease models and regenerative therapies for skin diseases, first demonstrating that iPSCs can provide the basis for modeling a human organ derived entirely from two different types of iPSC-derived cells.http://europepmc.org/articles/PMC3795682?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Munenari Itoh
Noriko Umegaki-Arao
Zongyou Guo
Liang Liu
Claire A Higgins
Angela M Christiano
spellingShingle Munenari Itoh
Noriko Umegaki-Arao
Zongyou Guo
Liang Liu
Claire A Higgins
Angela M Christiano
Generation of 3D skin equivalents fully reconstituted from human induced pluripotent stem cells (iPSCs).
PLoS ONE
author_facet Munenari Itoh
Noriko Umegaki-Arao
Zongyou Guo
Liang Liu
Claire A Higgins
Angela M Christiano
author_sort Munenari Itoh
title Generation of 3D skin equivalents fully reconstituted from human induced pluripotent stem cells (iPSCs).
title_short Generation of 3D skin equivalents fully reconstituted from human induced pluripotent stem cells (iPSCs).
title_full Generation of 3D skin equivalents fully reconstituted from human induced pluripotent stem cells (iPSCs).
title_fullStr Generation of 3D skin equivalents fully reconstituted from human induced pluripotent stem cells (iPSCs).
title_full_unstemmed Generation of 3D skin equivalents fully reconstituted from human induced pluripotent stem cells (iPSCs).
title_sort generation of 3d skin equivalents fully reconstituted from human induced pluripotent stem cells (ipscs).
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2013-01-01
description Recent generation of patient-specific induced pluripotent stem cells (PS-iPSCs) provides significant advantages for cell- and gene-based therapy. Establishment of iPSC-based therapy for skin diseases requires efficient methodology for differentiating iPSCs into both keratinocytes and fibroblasts, the major cellular components of the skin, as well as the reconstruction of skin structures using these iPSC-derived skin components. We previously reported generation of keratinocytes from human iPSCs for use in the treatment of recessive dystrophic epidermolysis bullosa (RDEB) caused by mutations in the COL7A1 gene. Here, we developed a protocol for differentiating iPSCs into dermal fibroblasts, which also produce type VII collagen and therefore also have the potential to treat RDEB. Moreover, we generated in vitro 3D skin equivalents composed exclusively human iPSC-derived keratinocytes and fibroblasts for disease models and regenerative therapies for skin diseases, first demonstrating that iPSCs can provide the basis for modeling a human organ derived entirely from two different types of iPSC-derived cells.
url http://europepmc.org/articles/PMC3795682?pdf=render
work_keys_str_mv AT munenariitoh generationof3dskinequivalentsfullyreconstitutedfromhumaninducedpluripotentstemcellsipscs
AT norikoumegakiarao generationof3dskinequivalentsfullyreconstitutedfromhumaninducedpluripotentstemcellsipscs
AT zongyouguo generationof3dskinequivalentsfullyreconstitutedfromhumaninducedpluripotentstemcellsipscs
AT liangliu generationof3dskinequivalentsfullyreconstitutedfromhumaninducedpluripotentstemcellsipscs
AT claireahiggins generationof3dskinequivalentsfullyreconstitutedfromhumaninducedpluripotentstemcellsipscs
AT angelamchristiano generationof3dskinequivalentsfullyreconstitutedfromhumaninducedpluripotentstemcellsipscs
_version_ 1725138283166433280